| abstract |
The present application is cis 3,4-dihydroxy-2- (3-methylbutanoyl) -5- (3-methylbutyl) -4- (4-methylpentanoyl) cyclopent-2-en-1-one Derivatives and substantially enantiomerically pure compositions thereof are provided. These derivatives include (+)-(4S, 5R) -3,4-dihydroxy-2- (3-methylbutanoyl) -5- (3-methylbutyl) -4- (4-methylpentanoyl) cyclo Pent-2-en-1-one, (-)-(4R, 5S) -3,4-dihydroxy-2- (3-methylbutanoyl) -5- (3-methylbutyl) -4- ( 4-methylpentanoyl) cyclopent-2-en-1-one, and salts and crystals thereof. Additionally, the present application uses the disclosed compounds and compositions to treat PPARĪ³, activate GPR120, inhibit inflammation, respond to PPARĪ³ regulation, treat conditions that respond to GPR120 regulation, and metabolic disorders such as diabetes. It provides a method for doing so. |